Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2019

Open Access 01-12-2019 | Human Papillomavirus | Review

Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa

Authors: Pingdwende Kader Aziz Bamogo, Christophe Brugidou, Drissa Sérémé, Fidèle Tiendrébéogo, Florencia Wendkuuni Djigma, Jacques Simpore, Séverine Lacombe

Published in: Virology Journal | Issue 1/2019

Login to get access

Abstract

Background

Developing African countries face health problems that they struggle to solve. The major causes of this situation are high therapeutic and logistical costs. Plant-made therapeutics are easy to produce due to the lack of the safety considerations associated with traditional fermenter-based expression platforms, such as mammalian cells. Plant biosystems are easy to scale up and inexpensive, and they do not require refrigeration or a sophisticated medical infrastructure. These advantages provide an opportunity for plant-made pharmaceuticals to counteract diseases for which medicines were previously inaccessible to people in countries with few resources.

Main body

The techniques needed for plant-based therapeutic production are currently available. Viral expression vectors based on plant viruses have greatly enhanced plant-made therapeutic production and have been exploited to produce a variety of proteins of industrial, pharmaceutical and agribusiness interest. Some neglected tropical diseases occurring exclusively in the developing world have found solutions through plant bioreactor technology. Plant viral expression vectors have been reported in the production of therapeutics against these diseases occurring exclusively in the third world, and some virus-derived antigens produced in plants exhibit appropriate antigenicity and immunogenicity. However, all advances in the use of plants as bioreactors have been made by companies in Europe and America. The developing world is still far from acquiring this technology, although plant viral expression vectors may provide crucial help to overcome neglected diseases.

Conclusion

Today, interest in these tools is rising, and viral amplicons made in and for Africa are in progress. This review describes the biotechnological advances in the field of plant bioreactors, highlights factors restricting access to this technology by those who need it most and proposes a solution to overcome these limitations.
Literature
1.
2.
3.
Updated_NTD_report2011_CS3_ok.indd. 2011;:25.
4.
Feldmann H, Jones S, Klenk H-D, Schnittler H-J. Timeline: Ebola virus: from discovery to vaccine. Nat Rev Immunol. 2003;3:677.PubMedCrossRef
5.
6.
7.
8.
9.
10.
11.
Giddings G, Allison G, Brooks D, Carter A. Transgenic plants as factories for biopharmaceuticals. Nat Biotechnol. 2000;18:1151.PubMedCrossRef
12.
MDG Report 2010 En 20100604 r14 Final.indd. Millenn Dev GOALS Rep. 2010:80.
13.
Daniell H, Streatfield SJ, Rybicki EP. Advances in molecular farming: key technologies, scaled up production and lead targets. Plant Biotechnol J. 2015;13:1011.PubMedPubMedCentralCrossRef
14.
Daniell H, Rai V, Xiao Y. Cold chain and virus-free oral polio booster vaccine made in lettuce chloroplasts confers protection against all three poliovirus serotypes. Plant Biotechnol J. 2019;17:1357.PubMedPubMedCentralCrossRef
15.
16.
17.
18.
Lee JH, Ko K. Production of recombinant anti-Cancer vaccines in plants. Biomol Ther. 2017;25:345.CrossRef
19.
Raskin I, Ribnicky DM, Komarnytsky S, Ilic N, Poulev A, Borisjuk N, et al. Plants and human health in the twenty-first century. Trends Biotechnol. 2002;20:522.PubMedCrossRef
20.
Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases 2004;430:8.
21.
Xu K, Evans DB, Carrin G, Aguilar-Rivera AM, Musgrove P, Evans T. Protecting Households From Catastrophic Health Spending. Health Aff (Millwood). 2007;26:972.CrossRef
22.
23.
McGarvey PB, Hammond J, Dienelt MM, Hooper DC, Fu ZF, Dietzschold B, et al. Expression of the rabies virus glycoprotein in transgenic tomatoes. Nat Biotechnol. 1995;13:1484.CrossRef
24.
Thanavala Y, Yang YF, Lyons P, Mason HS, Arntzen C. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc Natl Acad Sci. 1995;92:3358.PubMedCrossRefPubMedCentral
25.
Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol. 2000;18:1167.PubMedCrossRef
26.
Wigdorovitz A, Carrillo C, Dus Santos MJ, Trono K, Peralta A, Gómez MC, et al. Induction of a protective antibody response to foot and mouth disease virus in mice following Oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology. 1999;255:347.PubMedCrossRef
27.
Merlin M, Gecchele E, Capaldi S, Pezzotti M, Avesani L. Comparative evaluation of recombinant protein production in different biofactories: the green perspective. Biomed Res Int. 2014;2014:1.CrossRef
28.
Sparrow P, Broer I, Hood E, Eversole K, Hartung F, Schiemann J. Risk assessment and regulation of molecular farming - a comparison between Europe and US. Curr Pharm Des. 2013;19:5513.PubMedCrossRef
29.
30.
Breyer D, Goossens M, Herman P, Sneyers M. Biosafety considerations associated with molecular farming in genetically modified plants. J Med Plants Res. 2009;3:825.
31.
Ahmad K. Molecular farming: strategies, expression systems and bio-safety considerations. Czech J Genet Plant Breed. 2014;50:1–1.CrossRef
32.
Kapila J, De Rycke R, Van Montagu M, Angenon G. An agrobacterium-mediated transient gene expression system for intact leaves. Plant Sci. 1997;122:101.CrossRef
33.
Porceddu A, Falorni A, Ferradini N, Cosentino A, Calcinaro F, Faleri C, et al. Transgenic plants expressing human glutamic acid decarboxylase (GAD65), a major autoantigen in insulin-dependent diabetes mellitus. Mol Breed. 1999;5:553.CrossRef
34.
Zhang X, Buehner NA, Hutson AM, Estes MK, Mason HS. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotechnol J. 2006;4:419.PubMedCrossRef
35.
Rosenberg Y, Sack M, Montefiori D, Forthal D, Mao L, −Abanto SH, et al. Rapid High-Level Production of Functional HIV Broadly Neutralizing Monoclonal Antibodies in Transient Plant Expression Systems PLoS One 2013;8:e58724.PubMedPubMedCentralCrossRef
36.
Souza AC, Vasques RM, Inoue-Nagata AK, Lacorte C, Maldaner FR, Noronha EF, et al. Expression and assembly of Norwalk virus-like particles in plants using a viral RNA silencing suppressor gene. Appl Microbiol Biotechnol. 2013;97:9021.PubMedCrossRef
37.
Jones RM, Chichester JA, Manceva S, Gibbs SK, Musiychuk K, Shamloul M, et al. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses. Hum Vaccines Immunother. 2015;11:124.CrossRef
38.
39.
Mardanova ES, Blokhina EA, Tsybalova LM, Peyret H, Lomonossoff GP, Ravin NV. Efficient transient expression of recombinant proteins in plants by the novel pEff vector based on the genome of potato virus X. Front Plant Sci. 2017;8:247.PubMedPubMedCentralCrossRef
40.
Lacombe S, Bangratz M, Brizard J-P, Petitdidier E, Pagniez J, Sérémé D, et al. Optimized transitory ectopic expression of promastigote surface antigen protein in Nicotiana benthamiana , a potential anti-leishmaniasis vaccine candidate. J Biosci Bioeng. 2018;125:116.PubMedCrossRef
41.
42.
Johansen LK. Silencing on the spot. Induction and suppression of rna silencing in the agrobacterium-mediated transient expression system. PLANT Physiol. 2001;126:930.PubMedPubMedCentralCrossRef
43.
Brodersen P, Voinnet O. The diversity of RNA silencing pathways in plants. Trends Genet. 2006;22:268.PubMedCrossRef
44.
Incarbone M, Dunoyer P. RNA silencing and its suppression: novel insights from in planta analyses. Trends Plant Sci. 2013;18:382.PubMedCrossRef
45.
Lombardi R, Circelli P, Villani M, Buriani G, Nardi L, Coppola V, et al. High-level HIV-1 Nef transient expression in Nicotiana benthamiana using the P19 gene silencing suppressor protein of artichoke mottled Crinckle virus. BMC Biotechnol. 2009;9:96.PubMedPubMedCentralCrossRef
46.
Garabagi F, Gilbert E, Loos A, McLean MD, Hall JC. Utility of the P19 suppressor of gene-silencing protein for production of therapeutic antibodies in Nicotiana expression hosts. Plant Biotechnol J. 2012;10:1118.PubMedCrossRef
47.
Gleba Y, Klimyuk V, Marillonnet S. Viral vectors for the expression of proteins in plants. Curr Opin Biotechnol. 2007;18:134.PubMedCrossRef
48.
Yusibov V, Shivprasad S, Turpen TH, Dawson W, Koprowski H. Plant Viral Vectors Based on Tobamoviruses. In: Hammond J, McGarvey P, Yusibov V, editors. Plant Biotechnology. Berlin, Heidelberg: Springer Berlin Heidelberg; 2000. p. 81–94. doi:https://​doi.​org/​10.​1007/​978-3-642-60234.
49.
Turpen TH. Tobacco mosaic virus and the virescence of biotechnology. Philos Trans R Soc B Biol Sci. 1999;354:665.CrossRef
50.
Uhde-Holzem K, Schlösser V, Viazov S, Fischer R, Commandeur U. Immunogenic properties of chimeric potato virus X particles displaying the hepatitis C virus hypervariable region I peptide R9. J Virol Methods. 2010;166:12.PubMedCrossRef
51.
Mardanova ES, Kotlyarov RY, Kuprianov VV, Stepanova LA, Tsybalova LM, Lomonosoff GP, et al. Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors. BMC Biotechnol. 2015;15. https://​doi.​org/​10.​1186/​s12896-015-0164-6.
52.
Denis J, Majeau N, Acosta-Ramirez E, Savard C, Bedard M-C, Simard S, et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology. 2007;363:59.PubMedCrossRef
53.
Denis J, Acosta-Ramirez E, Zhao Y, Hamelin M-E, Koukavica I, Baz M, et al. Development of a universal influenza a vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine. 2008;26:3395.PubMedCrossRef
54.
Noris E, Poli A, Cojoca R, Rittà M, Cavallo F, Vaglio S, et al. A human papillomavirus 8 E7 protein produced in plants is able to trigger the mouse immune system and delay the development of skin lesions. Arch Virol. 2011;156:587.PubMedCrossRef
55.
Musiychuk K, Stephenson N, Bi H, Farrance CE, Orozovic G, Brodelius M, et al. A launch vector for the production of vaccine antigens in plants: plant-produced vaccines. Influenza Other Respir Viruses. 2007;1:19.PubMedPubMedCentralCrossRef
56.
Liu Z, Kearney CM. A tobamovirus expression vector for agroinfection of legumes and Nicotiana. J Biotechnol. 2010;147:151.PubMedCrossRef
57.
Steinmetz NF, Cho C-F, Ablack A, Lewis JD, Manchester M. Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells. Nanomed. 2011;6:351.CrossRef
58.
Rybicki EP, Martin DP. Virus-derived ssDNA vectors for the expression of foreign proteins in plants. Curr Top Microbiol Immunol. 2014;375:19.PubMed
59.
Regnard GL, Halley-Stott RP, Tanzer FL, Hitzeroth II, Rybicki EP. High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. Plant Biotechnol J. 2010;8:38.PubMedCrossRef
60.
Chung HY, Lee HH, Kim KI, Chung HY, Hwang-Bo J, Park JH, et al. Expression of a recombinant chimeric protein of hepatitis a virus VP1-fc using a replicating vector based on beet curly top virus in tobacco leaves and its immunogenicity in mice. Plant Cell Rep. 2011;30:1513.PubMedCrossRef
61.
Dugdale B, Mortimer CL, Kato M, James TA, Harding RM, Dale JL. In plant activation: an inducible, Hyperexpression Platform for Recombinant Protein Production in Plants. Plant Cell. 2013;25:2429.PubMedPubMedCentralCrossRef
62.
Kagale S, Uzuhashi S, Wigness M, Bender T, Yang W, Borhan MH, et al. TMV-gate vectors: gateway compatible tobacco mosaic virus based expression vectors for functional analysis of proteins. Sci Rep. 2012;2. https://​doi.​org/​10.​1038/​srep00874.
63.
Turpen T, Reinl S, Charoenvit Y, Hoffman S, Fallarme V, Grill L. Malarial epitopes expressed on the surface of recombinant tobacco mosaic-virus. Bio-Technol. 1995;13:53.
64.
Webster DE, Wang L, Mulcair M, Ma C, Santi L, Mason HS, et al. Production and characterization of an orally immunogenic Plasmodium antigen in plants using a virus-based expression system. Plant Biotechnol J. 2009;7:846.PubMedCrossRef
65.
Gleba Y, Marillonnet S, Klimyuk V. Engineering viral expression vectors for plants: the ‘full virus’ and the ‘deconstructed virus’ strategies. Curr Opin Plant Biol. 2004;7:182.PubMedCrossRef
66.
Avesani L, Marconi G, Morandini F, Albertini E, Bruschetta M, Bortesi L, et al. Stability of potato virus X expression vectors is related to insert size: implications for replication models and risk assessment. Transgenic Res. 2007;16:587.PubMedCrossRef
67.
Gleba Y, Klimyuk V, Marillonnet S. Magnifection?A new platform for expressing recombinant vaccines in plants. Vaccine. 2005;23:2042.PubMedCrossRef
68.
Liu L, Lomonossoff GP. Agroinfection as a rapid method for propagating cowpea mosaic virus-based constructs. J Virol Methods. 2002;105:343.PubMedCrossRef
69.
J√ottner G, Baulcombe DC, Fedorkin ON, Schiemann J, Atabekov JG, Morozov SYu. Complementation of a potato virus X mutant mediated by bombardment of plant tissues with cloned viral movement protein genes. J Gen Virol. 1997;78:2077.
70.
Ziegler-Graff V, Guilford PJ, Baulcombe DC. Tobacco rattle virus RNA-1 29K gene product potentiates viral movement and also affects symptom induction in tobacco. Virology. 1991;182:145.PubMedCrossRef
71.
Deom CM, Oliver MJ, Beachy RN. The 30-kilodalton gene product of tobacco mosaic virus potentiates virus movement. Science. 1987;237:389.PubMedCrossRef
72.
Kaplan IB, Shintaku MH, Li Q, Zhang L, Marsh LE, Palukaitis P. Complementation of virus movement in transgenic tobacco expressing the cucumber mosaic virus 3a gene. Virology. 1995;209:188.PubMedCrossRef
73.
van der Kuyl AC, Neeleman L, Bol JF. Complementation and recombination between alfalfa mosaic virus RNA3 mutants in tobacco plants. Virology. 1991;183:731.PubMedCrossRef
74.
Le DHT, Hu H, Commandeur U, Steinmetz NF. Chemical addressability of potato virus X for its applications in bio/nanotechnology. J Struct Biol. 2017;200:360.PubMedCrossRef
75.
Saunders K, Sainsbury F, Lomonossoff GP. Efficient generation of cowpea mosaicvirus empty virus-like particles by the proteolytic processing of precursors in insect cells and plants. Virology. 2009;393:329.PubMedCrossRef
76.
Gonzalez MJ, Plummer EM, Rae CS, Manchester M. Interaction of cowpea mosaic virus (CPMV) nanoparticles with antigen presenting cells in vitro and in vivo. PLoS One. 2009;4:e7981.PubMedPubMedCentralCrossRef
77.
Ren Y, Wong SM, Lim L-Y. Folic acid-conjugated protein cages of a plant virus: a novel delivery platform for doxorubicin. Bioconjug Chem. 2007;18:836.PubMedCrossRef
78.
Franke CE, Czapar AE, Patel RB, Steinmetz NF. Tobacco mosaic virus-delivered Cisplatin restores efficacy in platinum-resistant ovarian Cancer cells. Mol Pharm. 2018;15:2922.PubMedCrossRef
79.
Babin C, Majeau N, Leclerc D. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP. J Nanobiotechnology. 2013;11:10.PubMedPubMedCentralCrossRef
80.
Lebel M-È, Chartrand K, Tarrab E, Savard P, Leclerc D, Lamarre A. Potentiating Cancer immunotherapy using papaya mosaic virus-derived nanoparticles. Nano Lett. 2016;16:1826.PubMedCrossRef
81.
Madden AJ, Oberhardt B, Lockney D, Santos C, Vennam P, Arney D, et al. Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer. Nanomed. 2017;12:2519.CrossRef
82.
Narayanan KB, Han SS. Icosahedral plant viral nanoparticles - bioinspired synthesis of nanomaterials/nanostructures. Adv Colloid Interf Sci. 2017;248:1.CrossRef
83.
Massa S, Franconi R, Brandi R, Muller A, Mett V, Yusibov V, et al. Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine. 2007;25:3018.PubMedCrossRef
84.
Hamorsky KT, Grooms-Williams TW, Husk AS, Bennett LJ, Palmer KE, Matoba N. Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides. Antimicrob Agents Chemother. 2013;57:2076.PubMedPubMedCentralCrossRef
85.
Mohammadzadeh S, Roohvand F, Memarnejadian A, Jafari A, Ajdary S, Salmanian A-H, et al. Co-expression of hepatitis C virus polytope–HBsAg and p19-silencing suppressor protein in tobacco leaves. Pharm Biol. 2016;54:465.PubMedCrossRef
86.
Shukla S, Ablack AL, Wen AM, Lee KL, Lewis JD, Steinmetz NF. Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle Potato virus X. Mol Pharm. 2013;10:33.PubMedCrossRef
87.
88.
Sainsbury F, Lavoie P-O, D’Aoust M-A, Vézina L-P, Lomonossoff GP. Expression of multiple proteins using full-length and deleted versions of cowpea mosaic virus RNA-2. Plant Biotechnol J. 2007;0:071107010736001.CrossRef
89.
Mardanova ES, Kotlyarov RY, Kuprianov VV, Stepanova LA, Tsybalova LM, Lomonossoff GP, et al. High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin. Bioengineered. 2016;7:28.PubMedCrossRef
90.
Sainsbury F, Thuenemann EC, Lomonossoff GP. pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. Plant Biotechnol J. 2009;7:682.PubMedCrossRef
91.
Montague NP, Thuenemann EC, Saxena P, Saunders K, Lenzi P, Lomonossoff GP. Recent advances of cowpea mosaic virus-based particle technology. Hum Vaccin. 2011;7:383.PubMedCrossRef
92.
Meshcheriakova YA, Saxena P, Lomonossoff GP. Fine-tuning levels of heterologous gene expression in plants by orthogonal variation of the untranslated regions of a nonreplicating transient expression system. Plant Biotechnol J. 2014;12:718.PubMedPubMedCentralCrossRef
93.
Wang L, Kedzierski L, Wesselingh SL, Coppel RL. Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria. Infect Immun. 2003;71:2356.PubMedPubMedCentralCrossRef
94.
Herzog RW, Nichols TC, Su J, Zhang B, Sherman A, Merricks EP, et al. Oral tolerance induction in hemophilia B dogs fed with Transplastomic lettuce. Mol Ther. 2017;25:512.PubMedPubMedCentralCrossRef
95.
Su J, Zhu L, Sherman A, Wang X, Lin S, Kamesh A, et al. Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B. Biomaterials. 2015;70:84.PubMedPubMedCentralCrossRef
96.
Rosales-Mendoza S, Rubio-Infante N, Govea-Alonso DO, Moreno-Fierros L. Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV). Plant Cell Rep. 2012;31:495.PubMedCrossRef
97.
98.
Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, et al. HIV vaccine research: the way forward. Science. 2008;321:530.PubMedCrossRef
99.
Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine. 2007;25:510.PubMedCrossRef
100.
Voss G, Manson K, Montefiori D, Watkins DI, Heeney J, Wyand M, et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an Adjuvanted multicomponent protein vaccine. J Virol. 2003;77:1049.PubMedPubMedCentralCrossRef
101.
Maggiorella MT, Sernicola L, Crostarosa F, Belli R, Pavone-Cossut MR, Macchia I, et al. Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection. J Med Primatol. 2007;36:180.PubMedCrossRef
102.
Habibi P, Soccol CR, O’Keefe BR, Krumpe LRH, Wilson J, de Macedo LLP, et al. Gene-silencing suppressors for high-level production of the HIV-1 entry inhibitor griffithsin in Nicotiana benthamiana. Process Biochem. 2018;70:45.CrossRefPubMedPubMedCentral
103.
Ataie Kachoie E, Behjatnia SAA, Kharazmi S. Expression of human immunodeficiency virus type 1 (HIV-1) coat protein genes in plants using cotton leaf curl Multan betasatellite-based vector. PLoS One. 2018;13:e0190403.PubMedPubMedCentralCrossRef
104.
Marusic C, Vitale A, Pedrazzini E, Donini M, Frigerio L, Bock R, et al. Plant-based strategies aimed at expressing HIV antigens and neutralizing antibodies at high levels. Nef as a case study Transgenic Res. 2009;18:499.PubMed
105.
Orellana-Escobedo L, Rosales-Mendoza S, Romero-Maldonado A, Parsons J, Decker EL, Monreal-Escalante E, et al. An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice. Plant Cell Rep. 2015;34:425.PubMedCrossRef
106.
Karasev AV, Foulke S, Wellens C, Rich A, Shon KJ, Zwierzynski I, et al. Plant based HIV-1 vaccine candidate: tat protein produced in spinach. Vaccine. 2005;23:1875.PubMedCrossRef
107.
Barbante A, Irons S, Hawes C, Frigerio L, Vitale A, Pedrazzini E. Anchorage to the cytosolic face of the endoplasmic reticulum membrane: a new strategy to stabilize a cytosolic recombinant antigen in plants. Plant Biotechnol J. 2008;6:560.PubMedCrossRef
108.
109.
Dobaño C, Ubillos I, Jairoce C, Gyan B, Vidal M, Jiménez A, et al. RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study. BMC Med. 2019;17:157.PubMedPubMedCentralCrossRef
110.
Wang L, Webster DE, Campbell AE, Dry IB, Wesselingh SL, Coppel RL. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants. Int J Parasitol. 2008;38:103.PubMedCrossRef
111.
Ma C, Wang L, Webster DE, Campbell AE, Coppel RL. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen—the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1. Appl Microbiol Biotechnol. 2012;94:151.PubMedCrossRef
112.
Davoodi-Semiromi A, Schreiber M, Nalapalli S, Verma D, Singh ND, Banks RK, et al. Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Plant Biotechnol J. 2010;8:223.PubMedCrossRef
113.
Lee C, Kim H-H, Mi Choi K, Won Chung K, Choi Y, Jang M, et al. Murine immune responses to a Plasmodium vivax-derived chimeric recombinant protein expressed in Brassica napus. Malar J. 2011;10:106.PubMedPubMedCentralCrossRef
114.
115.
Cox JH, Dietzschold B, Schneider LG. Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun. 1977;16:754.
116.
Batista FRX, Moraes ÂM, Büntemeyer H, Noll T. Influence of culture conditions on recombinant Drosophila melanogaster S2 cells producing rabies virus glycoprotein cultivated in serum-free medium. Biologicals. 2009;37:108.PubMedCrossRef
117.
Ben Azoun S, Belhaj AE, Göngrich R, Gasser B, Kallel H. Molecular optimization of rabies virus glycoprotein expression in Pichia pastoris. Microb Biotechnol. 2016;9:355.PubMedPubMedCentralCrossRef
118.
Ramya R, Mohana Subramanian B, Sivakumar V, Senthilkumar RL, Sambasiva Rao KRS, Srinivasan VA. Expression and Solubilization of insect cell-based rabies virus glycoprotein and assessment of its immunogenicity and protective efficacy in mice. Clin Vaccine Immunol. 2011;18:1673.PubMedPubMedCentralCrossRef
119.
Yadav AS, Gahlot K, Gahlot GC, Asraf M, Yadav ML. Microsatellite DNA typing for assessment of genetic variability in Marwari breed of Indian goat. Vet World. 2015;8:848.PubMedPubMedCentralCrossRef
120.
Tiwari S, Mishra DK, Roy S, Singh A, Singh PK, Tuli R. High level expression of a functionally active cholera toxin B: rabies glycoprotein fusion protein in tobacco seeds. Plant Cell Rep. 2009;28:1827.PubMedCrossRef
121.
Shakin-Eshleman SH, Remaley AT, Eshleman JR, Wunner WH, Spitalnik SL. N-linked glycosylation of rabies virus glycoprotein. Individual sequons differ in their glycosylation efficiencies and influence on cell surface expression. J Biol Chem. 1992;267:10690.PubMed
122.
Yusibov V, Modelska A, Steplewski K, Agadjanyan M, Weiner D, Hooper DC, et al. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc Natl Acad Sci. 1997;94:5784.PubMedCrossRefPubMedCentral
123.
Strauss S. Ebola research fueled by bioterrorism threat. Can Med Assoc J. 2014;186:1206.CrossRef
124.
125.
Phoolcharoen W, Bhoo SH, Lai H, Ma J, Arntzen CJ, Chen Q, et al. Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana: Ebola immune complex expression. Plant Biotechnol J. 2011;9:807.PubMedCrossRef
126.
Lai H, He J, Engle M, Diamond MS, Chen Q. Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce: vaccine and antibody expression in lettuce. Plant Biotechnol J. 2012;10:95.PubMedCrossRef
127.
Saejung W, Fujiyama K, Takasaki T, Ito M, Hori K, Malasit P, et al. Production of dengue 2 envelope domain III in plant using TMV-based vector system. Vaccine. 2007;25:6646.PubMedCrossRef
128.
Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827.PubMedCrossRef
129.
Yanofsky VR, Patel RV, Goldenberg G. Genital warts: a comprehensive review. J Clin Aesthetic Dermatol. 2012;5:25.
130.
Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol. 2007;107(2 Suppl 1):S2–5.PubMedCrossRef
131.
Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol (Berl). 2004;193:35.CrossRef
132.
Thomas R, Steben M, Greenwald Z, Stutz M, Rodier C, DeAngelis F, et al. Recurrence of human papillomavirus external genital wart infection among high-risk adults in Montréal. Canada Sex Transm Dis. 2017;44:700.PubMedCrossRef
133.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12.PubMedCrossRef
134.
Ouedraogo RA, Zohoncon TM, Guigma SP, Angèle Traore IM, Ouattara AK, Ouedraogo M, et al. Oncogenic human papillomavirus infection and genotypes characterization among sexually active women in Tenkodogo at Burkina Faso. West Africa Papillomavirus Res. 2018;6:22.PubMedCrossRef
135.
Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccines Immunother. 2014;10:2147.CrossRef
136.
Huh WK, Joura EA, Giuliano AR, Iversen O-E, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet Lond Engl. 2017;390:2143.CrossRef
137.
Traore IMA, Zohoncon TM, Dembele A, Djigma FW, Obiri-Yeboah D, Traore G, et al. Molecular characterization of high-risk human papillomavirus in women in Bobo-Dioulasso. Burkina Faso BioMed Res Int. 2016;2016:7092583.PubMed
138.
CMR O, Djigma FW, Bisseye C, Sagna T, Zeba M, Ouermi D, et al. Epidemiology, characterization of genotypes of human papillomavirus in a population of women in Ouagadougou. J Gynecol Obstet Biol Reprod (Paris). 2011;40:633.CrossRef
139.
Ouédraogo C, Zohoncon TM, Traoré E, Ouattara S, Bado P, Ouedraogo C, et al. Distribution of high-risk human papillomavirus genotypes in precancerous cervical lesions in Ouagadougou, Burkina Faso. Clin Obstet Gynecol Reprod Med. 2016;2:141.CrossRef
140.
Djigma FW, Ouédraogo C, Karou DS, Sagna T, Bisseye C, Zeba M, et al. Prevalence and genotype characterization of human papillomaviruses among HIV-seropositive in Ouagadougou. Burkina Faso Acta Trop. 2011;117:202.PubMedCrossRef
141.
Zohoncon TM, Ouedraogo TC, Brun LVC, Obiri-Yeboah D, Djigma WF, Kabibou S, et al. Molecular epidemiology of high-risk human papillomavirus in high-grade cervical intraepithelial Neoplasia and in cervical Cancer in Parakou, Republic of Benin. Pak J Biol Sci PJBS. 2016;19:49.PubMedCrossRef
142.
Piras F, Piga M, De Montis A, Zannou AR, Minerba L, Perra MT, et al. Prevalence of human papillomavirus infection in women in Benin. West Africa Virol J. 2011;8:514.PubMed
143.
Jaquet A, Horo A, Charbonneau V, Ekouevi DK, Roncin L, Toure B, et al. Cervical human papillomavirus and HIV infection in women of child-bearing age in Abidjan, Côte d’Ivoire, 2010. Br J Cancer. 2012;107:556.PubMedPubMedCentralCrossRef
144.
Ndiaye C, Alemany L, Ndiaye N, Kamaté B, Diop Y, Odida M, et al. Human papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa: could HIV explain the differences? Trop Med Int Health TM IH. 2012;17:1432.PubMedCrossRef
145.
Zohoncon TM, Bisseye C, Djigma FW, Yonli AT, Compaore TR, Sagna T, et al. Prevalence of HPV high-risk genotypes in three cohorts of women in Ouagadougou (Burkina Faso). Mediterr J Hematol Infect Dis. 2013;5:e2013059.PubMedPubMedCentralCrossRef
146.
147.
Pastrana DV, Gambhira R, Buck CB, Pang Y-YS, Thompson CD, Culp TD, et al. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology. 2005;337:365.PubMedCrossRef
148.
Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A. 2008;105:5850.PubMedPubMedCentralCrossRef
149.
Schellenbacher C, Roden RBS, Kirnbauer R. Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res. 2017;231:166.PubMedCrossRef
150.
Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Müller M. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol. 2003;77:9211–20.PubMedPubMedCentralCrossRef
151.
Kohl T, Hitzeroth II, Stewart D, Varsani A, Govan VA, Christensen ND, et al. Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study. Clin Vaccine Immunol. 2006;13:845.PubMedPubMedCentralCrossRef
152.
Kohl TO, Hitzeroth II, Christensen ND, Rybicki EP. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum. BMC Biotechnol. 2007;7:56.PubMedPubMedCentralCrossRef
153.
Maclean J, Koekemoer M, Olivier AJ, Stewart D, Hitzeroth II, Rademacher T, et al. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol. 2007;88(Pt 5):1460.PubMedCrossRef
154.
Matić S, Masenga V, Poli A, Rinaldi R, Milne RG, Vecchiati M, et al. Comparative analysis of recombinant human papillomavirus 8 L1 production in plants by a variety of expression systems and purification methods. Plant Biotechnol J. 2012;10:410.PubMedCrossRef
155.
Varsani A, Williamson A-L, Stewart D, Rybicki EP. Transient expression of human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector. Virus Res. 2006;120:91.PubMedCrossRef
156.
Warzecha H, Mason HS, Lane C, Tryggvesson A, Rybicki E, Williamson A-L, et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol. 2003;77:8702.PubMedPubMedCentralCrossRef
157.
158.
Murphy DG, Sablon E, Chamberland J, Fournier E, Dandavino R, Tremblay CL. Hepatitis C virus genotype 7, a new genotype originating from Central Africa. J Clin Microbiol. 2015;53:967.PubMedPubMedCentralCrossRef
159.
Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol Orlando Fla. 2008;128:133.CrossRef
160.
Lechner F, Gruener NH, Urbani S, Uggeri J, Santantonio T, Kammer AR, et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol. 2000;30:2479.PubMedCrossRef
161.
Yerly D, Heckerman D, Allen TM, Chisholm JV, Faircloth K, Linde CH, et al. Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol. 2008;82:3147.PubMedPubMedCentralCrossRef
162.
Pniewski T, Kapusta J, Bociąg P, Wojciechowicz J, Kostrzak A, Gdula M, et al. Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation. J Appl Genet. 2011;52:125.PubMedCrossRef
163.
Assih M, Ouattara AK, Diarra B, Yonli AT, Compaore TR, Obiri-Yeboah D, et al. Genetic diversity of hepatitis viruses in west-African countries from 1996 to 2018. World J Hepatol. 2018;10:807.PubMedPubMedCentralCrossRef
164.
Kramvis A, Kew MC. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res Off J Jpn Soc Hepatol. 2007;37:S9.CrossRef
165.
166.
167.
Achour M, Younes BR, Kochbati L, Kahla S, Zeghal D, Maalej M, et al. Production of recombinant proteins GST L1, E6 and E7 tag HPV 16 for antibody detection of Tunisian cervical cancer patients. Afr J Biotechnol. 2009;8:369.
168.
Tombari W, Ghram A. Production of a truncated recombinant HA1 for influenza a H9 subtype screening. Biol J Int Assoc Biol Stand. 2016;44:546.
169.
Thomson JA. The role of biotechnology for agricultural sustainability in Africa. Philos Trans R Soc B Biol Sci. 2008;363:905.CrossRef
170.
Halley-Stott RP, Tanzer F, Martin DP, Rybicki EP. The complete nucleotide sequence of a mild strain of bean yellow dwarf virus. Arch Virol. 2007;152:1237.PubMedCrossRef
171.
Obembe OO. The plant biotechnology flight: is Africa on board? Afr J Biotechnol. 2010;9:4300–8.
172.
Brugidou C, Holt C, Ngon A, Yassi M, Zhang S, Beachy R, Fauquet C. Synthesis of an infectious full-length cDNA clone of rice yellow mottle virus andmutagenesis of the coat protein. Virology. 1995;206:108.PubMedCrossRef
173.
Koala M, Traoré VSE, Sérémé D, Neya BJ, Brugidou C, Barro N, et al. Imperata yellow mottle virus: an emerging threat to maize, Sorghum and Pearl Millet in Burkina Faso. Agric Sci. 2017;8:397.
174.
Tiendrébéogo F, Lefeuvre P, Hoareau M, Traoré VSE, Barro N, Péréfarres F, et al. Molecular and biological characterization of pepper yellow vein Mali virus (PepYVMV) isolates associated with pepper yellow vein disease in Burkina Faso. Arch Virol. 2011;156:483.PubMedCrossRef
175.
Tiendrebeogo F, Traoré V, Nicolas B, Traore A, Gnissa K, Traore O. Characterization of pepper yellow vein Mali virus in Capsicum sp. in Burkina Faso. Plant Pathol J. 2008;7:155.CrossRef
176.
Sérémé D, Lacombe S, Konaté M, Pinel-Galzi A, Traoré VSE, Hébrard E, et al. Biological and molecular characterization of a putative new sobemovirus infecting Imperata cylindrica and maize in Africa. Arch Virol. 2008;153:1813.PubMedCrossRef
177.
Secretariat of the Convention on Biological Diversity. Nagoya protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization. Montreal: Secretariat of the Convention on Biological Diversity; 2011.
Metadata
Title
Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa
Authors
Pingdwende Kader Aziz Bamogo
Christophe Brugidou
Drissa Sérémé
Fidèle Tiendrébéogo
Florencia Wendkuuni Djigma
Jacques Simpore
Séverine Lacombe
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2019
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-019-1263-0

Other articles of this Issue 1/2019

Virology Journal 1/2019 Go to the issue

Research

Porcine transmissible gastroenteritis virus inhibits NF-κB activity via nonstructural protein 3 to evade host immune system

Research

Evaluation of novel rapid detection kits for dengue virus NS1 antigen in Dhaka, Bangladesh, in 2017

Research

Management of ASC-US/HPV positive post-menopausal woman

Research

Downregulation of microRNA-30a-5p contributes to the replication of duck enteritis virus by regulating Beclin-1-mediated autophagy

Research

The tyrosine 73 and serine 83 dephosphorylation of H1N1 swine influenza virus NS1 protein attenuates virus replication and induces high levels of beta interferon

Short report

Mapping of CD4+ T-cell epitopes in bovine leukemia virus from five cattle with differential susceptibilities to bovine leukemia virus disease progression

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits